Literature DB >> 19574921

Strategies to enhance cardiovascular disease prevention in patients with diabetes.

Matteo Anselmino1, Lars Rydén.   

Abstract

PURPOSE OF REVIEW: To describe current strategies to enhance cardiovascular disease (CVD) prevention in patients with abnormal glucose regulation. RECENT
FINDINGS: Early detection of glucose abnormalities and a multifactorial approach to all modifiable risk factors are effective strategies to reduce the burden of CVD in patients with diabetes mellitus. Available evidence suggests that an overly aggressive approach to lowering of glucose may contribute to complications; different hypoglycaemic agents may vary in the likelihood with which their use may give rise to complications. Thus, a decrease of glucose levels below that recommended in available guidelines is not recommended.
SUMMARY: Given its increasing prevalence and its substantial concomitant risk for CVD, diabetes mellitus can no longer be perceived as an endocrine disorder only bearing high risk of microvascular complications. Further research involving prospective clinical trials will be necessary to clarify the benefits of early detection and treatment of diabetes in preventing the subsequent development or exacerbation of CVD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19574921     DOI: 10.1097/HCO.0b013e32832ec3c5

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  2 in total

Review 1.  Insulin resistance, diabetes, and cardiovascular risk.

Authors:  Francesco Paneni; Sarah Costantino; Francesco Cosentino
Journal:  Curr Atheroscler Rep       Date:  2014-07       Impact factor: 5.113

2.  Sympathovagal imbalance contributes to prehypertension status and cardiovascular risks attributed by insulin resistance, inflammation, dyslipidemia and oxidative stress in first degree relatives of type 2 diabetics.

Authors:  Gopal Krushna Pal; Chandrasekaran Adithan; Palghat Hariharan Ananthanarayanan; Pravati Pal; Nivedita Nanda; Thiyagarajan Durgadevi; Venugopal Lalitha; Avupati Naga Syamsunder; Tarun Kumar Dutta
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.